Wilmington Savings Fund Society FSB Purchases 11,312 Shares of Solventum Co. (NYSE:SOLV)

Wilmington Savings Fund Society FSB raised its stake in Solventum Co. (NYSE:SOLV - Free Report) by 196.7% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 17,062 shares of the company's stock after acquiring an additional 11,312 shares during the quarter. Wilmington Savings Fund Society FSB's holdings in Solventum were worth $1,190,000 at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in SOLV. MML Investors Services LLC increased its stake in Solventum by 3.2% during the third quarter. MML Investors Services LLC now owns 5,345 shares of the company's stock worth $373,000 after acquiring an additional 168 shares during the last quarter. Tokio Marine Asset Management Co. Ltd. increased its stake in Solventum by 4.2% during the third quarter. Tokio Marine Asset Management Co. Ltd. now owns 4,966 shares of the company's stock worth $346,000 after acquiring an additional 200 shares during the last quarter. National Bank of Canada FI boosted its position in shares of Solventum by 4.0% in the second quarter. National Bank of Canada FI now owns 6,093 shares of the company's stock worth $314,000 after buying an additional 236 shares during the period. IVC Wealth Advisors LLC boosted its position in shares of Solventum by 5.0% in the third quarter. IVC Wealth Advisors LLC now owns 6,649 shares of the company's stock worth $464,000 after buying an additional 318 shares during the period. Finally, KKM Financial LLC boosted its position in shares of Solventum by 7.9% in the third quarter. KKM Financial LLC now owns 4,367 shares of the company's stock worth $304,000 after buying an additional 319 shares during the period.

Analysts Set New Price Targets

SOLV has been the subject of a number of analyst reports. Piper Sandler increased their price target on Solventum from $71.00 to $75.00 and gave the company a "neutral" rating in a report on Friday, November 8th. Wolfe Research assumed coverage on Solventum in a research note on Thursday, September 26th. They set a "peer perform" rating for the company. Stifel Nicolaus began coverage on Solventum in a report on Tuesday, October 8th. They set a "buy" rating and a $82.00 price objective for the company. BTIG Research began coverage on Solventum in a research note on Thursday, September 5th. They issued a "neutral" rating on the stock. Finally, Mizuho began coverage on Solventum in a research note on Wednesday, December 4th. They issued a "neutral" rating and a $70.00 price objective on the stock. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating and one has issued a buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Hold" and a consensus price target of $68.29.

Solventum Price Performance

Shares of Solventum stock traded down $0.45 during trading on Friday, hitting $69.56. The company's stock had a trading volume of 637,853 shares, compared to its average volume of 824,329. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.83 and a current ratio of 1.15. Solventum Co. has a 52 week low of $47.16 and a 52 week high of $96.05. The stock has a 50-day moving average price of $70.91 and a two-hundred day moving average price of $63.22.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.